

Filed on behalf of: Breckenridge Pharmaceutical, Inc.

By: Daniel R. Evans
Registration No. 55,868
MERCHANT & GOULD P.C.
191 Peachtree Street, NE
Suite 3800
Atlanta, GA 30303
Main Telephone: 404.954.5100
Main Facsimile: 612.332.9081

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE

PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.

Petitioner, v.

NOVARTIS PHARMACEUTICALS CORPORATION

Patent Owner.

Case: IPR2017-01592
U.S. Patent No. 8,410,131

PETITIONER'S UPDATED EXHIBIT LIST

DATED MARCH 16, 2018

Exhibit Number	Exhibit Description
1001	U.S. Patent No. 8,410,131 ("the '131 patent")
1002	PCT Published Application No. WO 01/51049 A1, <i>O-Methylated Rapamycin Derivatives for Alleviation and Inhibition of Lymphoproliferative Disorders</i> , to Wasik et al. ("Wasik")
1003	PCT Published Application No. WO 00/33878 A2, <i>Macrolides</i> , to Navarro et al. ("Navarro")
1004	Crowe et al., <i>Absorption and Intestinal Metabolism of SDZ-RAD and Rapamycin in Rats</i> , <i>Drug Metab. Disp.</i> (1999), 27(5): 627-632 ("Crowe")
1005	Luan et al., <i>Sirolimus Prevents Tumor Progression: mTOR Targeting for the Inhibition of Neoplastic Progression</i> , <i>Am. J. Transplant.</i> (2001) 1 Suppl 1, 243 (Abstr. No. 428) ("Luan")
1006	Hidalgo et al., <i>The Rapamycin-sensitive Signal Transduction Pathway as a Target for Cancer Therapy</i> , <i>Oncogene</i> (2000) 19(56): 6680-6686 ("Hidalgo")
1007	Alexandre et al., <i>CCI-779, A new Rapamycin Analog, Has Antitumor Activity at Doses Including Only Mild Cutaneous Effects and Mucositis: Early Results of an Ongoing Phase I Study</i> , <i>Clin. Cancer Res. Suppl.</i> (1999) 5: 3730s, Abstr. No. 7 (AACR-NCI-EORTC International Conference, November 16-19, 1999 held in Washington, DC) ("Alexandre")
1008	Schuler et al., <i>SDZ RAD, A New Rapamycin Derivative</i> , <i>Transplantation</i> (1997) 64(1): 36-42 ("Schuler")

1009	Neumayer et al., <i>Entry-into-human Study with the Novel Immunosuppressant SDZ RAD in Stable Renal Transplant Patients</i> , Br. J. Clin. Pharmacol. (1999) 48(5): 694-703 ("Neumayer")
1010	Declaration of Allan J. Pantuck, M.D. in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent No. 8,410,131
1011	RAPAMUNE [®] (sirolimus) Oral Solution RAPAMUNE [®] Approval Letter and approved labeling
1012	Great Britain patent application (GB 0104072.4, "GB '072" or "the '072 priority application")
1013	Great Britain patent application (GB0124957.2, "GB '957" or "the '957 priority application")
1014	International Patent Application No. PCT/EP02/01714 ("the '714 PCT Application")
1015	IPR Final Rules
1016	Dancey, J. E., <i>Rapamycin-Sensitive Signal-Transduction Pathways: Protein Translation Control of Cell Proliferation</i> , ASCO Educational Book (2000) 68-75 ("Dancey")
1017	Sorbera et al, <i>SDZ-RAD</i> , Drugs of the Future (1999) 24(1): 22-29 ("Sorbera")
1018	U.S. Patent No. 5,362,718, to Skotnicki et al. ("Skotnicki '718")
1019	U.S. Patent No. 5,665,772 to Cottens et al. ("Cottens '772 patent")
1020	Sedrani et al., <i>Chemical Modification of Rapamycin: The Discovery of SDZ RAD</i> , Transplantation Proc.(1998) 30(5): 2192-2194 ("Sedrani")

1021	PCT Published Application No. WO 97/47317 A1, Combination of a Somatostatin Analogue and a Rapamycin, to G. Weckbecker ("Weckbecker")
1022	U.S. Patent No. 6,331,547, Water Soluble SDZ RAD Esters, which issued to Zhu et al. on December 18, 2001 from U.S. Provisional Patent Application No. 60/183,035 filed on August 18, 1999 to Zhu ("Zhu '547 patent")
1023	U.S. Patent Application Publication No. 2002/0183239 A1, Antineoplastic Combinations, which published on December 5, 2002 from an application filed on April 6, 2001, to Gibbons ("Gibbons US '239")
1024	U.S. Patent Application Publication No. 2003/0008923 A1, Antineoplastic Combinations, which published on January 9, 2003 from an application filed on June 1, 2001 to Dukart ("Dukart US '923")
1025	Flowcharts for 35 U.S.C. § 102(e) Dates ("102(e) Date Flowchart")
1026	Published Application No. WO 94/09010 A1, O-Alkylated Rapamycin Derivatives and their use, particularly as immunosuppressants, to Cottens et al. ("Cottens WO '010")
1027	Selected portions of Prosecution History Documents ("May 10, 2010 Amendment re. Cottens WO '010")
1028	Curriculum Vitae of Allan J. Pantuck, M.D.
1029	2015 Orange Book, "35th Edition (2015) with respect to AFINITOR® ("2015 Orange Book ")
1030	Alexandre, Raymond, et al., La rapamycine et le CCI- 779, Bull. Cancer (1999) 86(10): 808-811 ("Alexandre" and Raymond")

1031	Boni et al., <i>Pharmacokinetics of escalating doses of CCI-779 in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Solid Tumors</i> , Eur. J. Cancer (2001) 37(Suppl. 6): S68 (Abstr. No. 242) (The 11 th ECCO October 21-25, 2001 meeting held in Lisbon, Portugal) ("Boni")
1032	Dinney et al., <i>Biology of Metastasis: Studies in Renal Cancer (17-24)</i> , in Principles and Practice of Genitourinary Oncology (Raghavan et al. eds., 1997) ("Dinney")
1033	Shi et al., <i>Rapamycin enhances Apoptosis and Increases Sensitivity to Cisplatin in Vitro</i> , Cancer Research (1995) 55(9): 1982-1988 ("Shi")
1034	Fosså et al., <i>Survival of Patients with Advanced Urothelial Cancer treated with Cisplatin-based Chemotherapy</i> , Brit. J. Cancer (1996) 74: 1655-1659 ("Fosså")
1035	Motzer et al., <i>Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma</i> , J. Clin. Oncol. (1999) 17(8): 2530-2540 ("Motzer et al.")
1036	PCT Published Application No. WO 02/40000 A2, <i>Use of CCI-779 as an Antineoplastic Agent</i> , to Dukart et al. ("Dukart WO '000")
1037	PCT Published Application No. WO 02/080975 A1, <i>Antineoplastic Combinations such as Rapamycin together with Gemcitabine or Fluorouracil</i> , to Gibbons et al. ("Gibbons WO '975")
1038	PCT Published Application No. WO 02/098416 A2, <i>Antineoplastic Combinations</i> , to Dukart et al. ("Dukart WO '416")
1039	U.S. Patent Application Publication No. 2002/0091137 A1, <i>Use of CCI-779 as an Antineoplastic Agent</i> , which published on July 11, 2002, to Dukart ("Dukart '137")

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.